An open 6-week study on the efficacy of agomelatine in 35 patients with a single depressive episode or recurrent depression (ICD-10) with marked anxiety was carried out. The high efficacy and safety of agomelatine in the treatment of mild and moderate depression concomitant to anxiety disorders was demonstrated. The reduction in depressive symptoms and sleep disorders was noted from the first week of treatment and in anxiety disorders - from the second week. To the end of the study, the therapeutic effect was seen in 71.9% patients, the remission criteria were achieved in 68.8% patients.